Etonitazene

Etonitazene

Clinical data
ATC code	none
Legal status
Legal status	CA: Schedule I DE: Anlage I (Authorized scientific use only) US: Schedule I
Identifiers
IUPAC name 2-(p-Ethoxybenzyl)-1-diethylaminoethyl-5-nitrobenzimidazole
CAS Number	911-65-9 N
PubChem CID	13493
IUPHAR/BPS	1624
DrugBank	DB01462 Y
ChemSpider	12908 Y
UNII	9U3GT3353T
ChEMBL	ChEMBL312040 Y
CompTox Dashboard (EPA)	DTXSID6048919
ECHA InfoCard	100.011.827
Chemical and physical data
Formula	C22H28N4O3
Molar mass	396.48 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=C(CC2=NC3=C(N2CCN(CC)CC)C=CC(N(=O)=O)=C3)C=C1
InChI InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3 Y Key:PXDBZSCGSQSKST-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Etonitazene is a potent analgesic drug shown to be approximately 1000–1500x the potency of morphine in animal models but only 60x in man. It is one of several benzimidazole opioids, and is structurally related to clonitazene (where the p-ethoxybenzyl group is replaced by a p-chlorobenzyl group; however, clonitazene itself has only 3x the potency of morphine).

Later work discovered that if a carboxide moiety is placed onto the carbon between the benzimidazole and the p-ethoxybenzyl, compounts up to 4x more potent were discovered It is of interest that the extra hydrogen-bond acceptor overlays the nociceptin receptor such as MCOPPB.

It has a strong dependency potential similar to that of morphine, and a strong tendency to produce respiratory depression, and is therefore not used in humans. It is however useful in addiction studies on animals. It is often used in studies requiring the animals to drink or ingest the opiate because it is not as bitter as the opiate salts, i.e., morphine sulfate.

It is the most potent benzimidazole opioid currently known. Other analogues of considerable potency are as follows:

Drug name	R	Analgesic Potency (Morphine = 1)
Etonitazene	ethoxy	1000
Clonitazene	chlorine	3
Nitazene	hydrogen	2
	methyl	10
	ethyl	30
	propyl	50
	tert-butyl	2
	methoxy	100
	isopropoxy	500
	butoxy	200
	acetoxy	5
	methylthio	50
	ethylthio	30

Of these analogues, only etonitazene and clonitazene are explicitly listed as illegal drugs under UN convention and so are illegal throughout the world. The rest would only be illegal in countries such as the USA, Australia and New Zealand that have laws equivalent to the Federal Analog Act. In the United States it is a Schedule I Narcotic controlled substance with a DEA ACSCN of 9624 and a zero annual manufacturing quota as of 2013.

Etonitazene has proved very important in mapping out the opiate receptor and some experimental compounds in which phenolic groupings have been replaced with nitro groupings have proved more active than the parent compound.

Illicit production and sale of etonitazene has been limited. This compound was identified on the illegal drug market in Moscow in 1998, appeared to have been illicitly manufactured, and was primarily smoked as pre-laced cigarettes. In another case a chemist at Morton Thiokol called Thomas K Highsmith produced the compound and placed it in a nasal inhaler.

Synthesis

Etonitazene and its related opioid agonist benzimidazoles were discovered in the late 1950s, by a team of Swiss researchers working at the pharmaceutical firm CIBA (now Novartis). One of the first compounds investigated by the Swiss team was 1-(β-diethylaminoethyl)-2-benzylbenzimidazole, which was found to possess 10% of the analgesic activity of morphine when tested in rodent bioassays. This finding encouraged the group to begin a comprehensive systematic study of 2-benzylbenzimidazoles and to establish the structure-activity relationship of this new family of analgesics. Two general synthetic methods were developed for the preparation of these compounds.

The first method involved the condensation of o-phenylenediamine with phenylacetonitrile to form a 2-benzylbenzimidazole. The benzimidazole is then alkylated with the desired 1-chloro-2-dialkylaminoethane, forming the final product. This particular procedure was most useful for the preparation of benzimidazoles that lacked substituents on the benzene rings. A diagram of this method is displayed below.

Etonitazene 1960 unsubstituted simple synthesis

The most versatile synthesis developed by the Swiss team first involved alkylation of 2,4-dinitrochlorobenzene with 1-amino-2-diethylaminoethane to form N-(β-Diethylaminoethyl)-2,4-dinitroaniline [aka: N'-(2,4-Dinitrophenyl)-N,N-diethyl-ethane-1,2-diamine]. The 2-nitro substituent on the 2,4-dinitroaniline compound is then selectively reduced to the corresponding primary amine by utilizing ammonium sulfide as the reducing agent. The ammonium sulfide can be formed in situ by the addition of concentrated aqueous ammonium hydroxide followed by saturation of the solution with hydrogen sulfide gas. The intermediate formed by the selective reduction of the 2-nitro substituent, 2-(β-Diethylaminoethylamino)-5-nitroaniline, is then reacted with the hydrochloride salt of the imino ethyl ether of 4-ethoxyphenylacetonitrile (aka: p-ethoxybenzyl cyanide). The imino ether, 2-(4-Ethoxyphenyl)-acetimidic acid ethyl ester hydrochloride, is prepared by dissolving the 4-substituted benzyl cyanide in a mixture of anhydrous ethanol and chloroform and then saturating this solution with dry hydrogen chloride gas. The reaction between the 2-(β-dialkylaminoalkylamine)-5-nitroaniline and the HCl salt of the imino ethyl ether results in the formation of etonitazene. This procedure is particularly useful in the preparation of the 4-, 5-, 6-, and 7-nitrobenzimidazoles. Varying the choice of the substituted phenylacetic acid imino ether affords compounds with a diversity of substituents on the benzene ring at the 2- position. A diagram of this particular synthesis as it applies to the preparation of etonitazene is shown below.

A particularly novel, high-yielding synthesis of etonitazene was developed by FI Carroll and MC Coleman in the mid-1970s The authors were tasked with the preparation of large quantities of etonitazene, but found the conventional synthesis to be inadequate. The problem with the conventional synthesis was the lability of the imino ether reactant, 2-(4-Ethoxyphenyl)-acetimidic acid ethyl ester (prepared by reacting 4-ethoxyphenylacetonitrile with ethanolic HCl). The imino ether necessitated the use of anhydrous reaction conditions and was inconvenient to prepare in large quantities. This led the authors to experiment with the use of a coupling reagent, EEDQ (N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline), in order to promote the condensation of 2-(2-diethylaminoethylamino)-5-nitroaniline with 4-ethoxyphenylacetic acid. Incredibly, the authors discovered that when this condensation was performed in the presence of 2 or more molar equivalents of EEDQ (added portionwise in 3 steps) in THF at 50°C for 192 hours (8 days), a near quantitative yield (100%) of etonitazene was obtained. In addition to the impressive improvement in yield over the conventional procedure, the work up procedure was greatly simplified since quinoline, carbon dioxide, and ethanol were the only by-products formed. A diagram of this procedure is shown below.

A 2011 publication [J. Org. Chem., 2011, 76(23), 9577-9583] from a South Korean team outlined a novel, one-pot synthesis for substituted and unsubstituted 2-benzyl-benzimidazoles that can be easily adapted to the preparation of etonitazene. The three component synthesis of the direct etonitazene precursor, 2-(4-Ethoxybenzyl)-5-nitro-1H-benzoimidazole, consists of a 2-Bromo- or 2-Iodo-5-nitro-phenylamine (1.0 molar equivalent), a 4-substituted benzaldehyde (1.2 equiv), and sodium azide (2 equiv). The 2-Halo-5-nitro-phenylamine requires a bromo or iodo group for optimal activity. 2-Chloro-phenylamines are completely unreactive. In addition to these three components, the reaction was optimized in the presence of 0.05 molar equivalents (5 mol%) of a catalyst, copper(I) chloride, and 5 mol% of ligand, TMEDA (tetramethylethylenediamine). After heating these components at 120°C for 12 hours in DMSO, the direct etonitazene precursor, 2-(4-Ethoxybenzyl)-5-nitro-1H-benzoimidazole, was formed in an approx 80-90% yield. The secondary amine nitrogen of 2-(4-Ethoxybenzyl)-5-nitro-1H-benzoimidazole was then alkylated with (2-Chloroethyl)diethylamine to form etonitazene. A diagram of this synthesis is shown below.